[go: up one dir, main page]

PE20091528A1 - VACCINES AGAINST MALARIA - Google Patents

VACCINES AGAINST MALARIA

Info

Publication number
PE20091528A1
PE20091528A1 PE2008002169A PE2008002169A PE20091528A1 PE 20091528 A1 PE20091528 A1 PE 20091528A1 PE 2008002169 A PE2008002169 A PE 2008002169A PE 2008002169 A PE2008002169 A PE 2008002169A PE 20091528 A1 PE20091528 A1 PE 20091528A1
Authority
PE
Peru
Prior art keywords
antigen
malaria
particle
immunogenous
dbp
Prior art date
Application number
PE2008002169A
Other languages
Spanish (es)
Inventor
Dominique Ingrid Lemoine
Wauters Florence Emilie Jeanne Francoise
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40584700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091528(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20091528A1 publication Critical patent/PE20091528A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFIERE A UN COMPONENTE PARA UNA VACUNA CONTRA LA MALARIA QUE COMPRENDE: (A) UNA PARTICULA INMUNOGENA RTS, S; Y/O (B) UNA PARTICULA INMUNOGENA QUE SE DERIVA DE LA PROTEINA CS DE UNA O MAS CEPAS DE P. VIVAX Y EL ANTIGENO S DE LA HEPATITIS B Y OPCIONALMENTE EL ANTIGENO S SIN FUSIONAR, O (C) UNA PARTICULA INMUNOGENA QUE COMPRENDE RST, CSV-S Y OPCIONALMENTE EL ANTIGENO S SIN FUSIONAR, Y (D) UN AGENTE ESTABILIZANTE QUE COMPRENDE UN AGENTE ESTABILIZANTE CON AL MENOS UN GRUPO FUNCIONAL TIOL TAL COMO N-ACETIL CISTEINA MONOGLICEROL, CISTEINA O SUS MEZCLAS; ADEMAS COMPRENDE UN ANTIGENO DE MALARIA ADICIONAL A PARTIR DE DBP TAL COMO Pv RII EL DOMINIO DE UNION DE DBP, PvTRAP, ENTRE OTROS. SE REFIERE TAMBIEN A UN METODO DE PREPARACION DE UNA FORMA FARMACEUTICA LIQUIDA. DICHO COMPONENTE ES DE UTILIDAD EN LA PREVENCION DE INFECCIONES DE MALARIAREFERS TO A COMPONENT FOR A VACCINE AGAINST MALARIA INCLUDING: (A) AN IMMUNOGENOUS PARTICLE RTS, S; AND / OR (B) AN IMMUNOGENOUS PARTICLE DERIVED FROM CS PROTEIN FROM ONE OR MORE P. VIVAX STRAINS AND HEPATITIS ANTIGEN S BY OPTIONALLY UNFUSED S ANTIGEN, OR (C) AN IMMUNOGENIC PARTICLE INCLUDING RST , CSV-S AND OPTIONALLY UNFUSIONED ANTIGEN S, AND (D) A STABILIZING AGENT INCLUDING A STABILIZING AGENT WITH AT LEAST ONE THIOL FUNCTIONAL GROUP SUCH AS N-ACETYL CYSTEINE MONOGLYCEROL, CYSTEINE OR THEIR MIXTURES; ALSO INCLUDES AN ADDITIONAL MALARIA ANTIGEN FROM DBP SUCH AS Pv RII THE UNION DOMAIN OF DBP, PvTRAP, AMONG OTHERS. IT ALSO REFERS TO A METHOD OF PREPARING A LIQUID PHARMACEUTICAL FORM. SAID COMPONENT IS USEFUL IN THE PREVENTION OF MALARIA INFECTIONS

PE2008002169A 2007-12-21 2008-12-19 VACCINES AGAINST MALARIA PE20091528A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1576207P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
PE20091528A1 true PE20091528A1 (en) 2009-10-29

Family

ID=40584700

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002169A PE20091528A1 (en) 2007-12-21 2008-12-19 VACCINES AGAINST MALARIA

Country Status (22)

Country Link
US (1) US20100272745A1 (en)
EP (1) EP2234637A2 (en)
JP (1) JP2011507816A (en)
KR (1) KR20100109556A (en)
CN (1) CN102026657A (en)
AP (1) AP2010005296A0 (en)
AR (1) AR071741A1 (en)
AU (1) AU2008339980A1 (en)
BR (1) BRPI0822098A2 (en)
CA (1) CA2708716A1 (en)
CL (1) CL2008003808A1 (en)
CO (1) CO6300963A2 (en)
CR (1) CR11577A (en)
DO (1) DOP2010000189A (en)
IL (1) IL206308A0 (en)
MA (1) MA32030B1 (en)
MX (1) MX2010006984A (en)
PE (1) PE20091528A1 (en)
TW (1) TW200940086A (en)
UY (1) UY31569A1 (en)
WO (1) WO2009080715A2 (en)
ZA (1) ZA201004304B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142278A1 (en) * 2012-03-22 2013-09-26 New York University Plasmodium vivax vaccine compositions
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogs, methods for their production, preparations containing them and their uses
CN105233296B (en) * 2015-11-24 2018-08-17 江苏省农业科学院 Heat-resisting lyophilized protecting agent and its preparation method and application for duck virus hepatitis live vaccine
GB201608821D0 (en) * 2016-05-19 2016-07-06 Isis Innovation Vaccines
US20200164065A1 (en) * 2017-04-25 2020-05-28 Adjuvance Technologies, Inc. Triterpene saponin analogues
CA3061205A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
AU2018350887A1 (en) 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
JP2022526334A (en) 2019-03-25 2022-05-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods of Treatment of Tauopathy Disorders by Targeting New Tau Species

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
CA2252565C (en) * 1996-04-26 2010-11-23 David B. Volkin Dna vaccine formulations
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
DE69838992T2 (en) * 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Oil-in-water emulsions with saponins
CN1359299A (en) * 1999-06-02 2002-07-17 人类基因组科学公司 Keratinocyte growth factor-2-formulations
KR100785601B1 (en) * 2003-11-21 2007-12-14 화이자 프로덕츠 인크. The use of antibiotics as vaccine adjuvants
CN102702359A (en) * 2004-02-02 2012-10-03 泰勒公司 Identification of novel igE epitopes
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1962910A4 (en) * 2005-12-15 2010-03-31 Aeras Global Tb Vaccine Found NEW PRIME BOOST COMBINATION FROM WEAKEN MYCOBACTERIA
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions

Also Published As

Publication number Publication date
AP2010005296A0 (en) 2010-06-30
CO6300963A2 (en) 2011-07-21
MA32030B1 (en) 2011-01-03
CN102026657A (en) 2011-04-20
WO2009080715A2 (en) 2009-07-02
WO2009080715A3 (en) 2009-11-12
CR11577A (en) 2010-09-03
KR20100109556A (en) 2010-10-08
UY31569A1 (en) 2009-08-03
EP2234637A2 (en) 2010-10-06
AU2008339980A1 (en) 2009-07-02
US20100272745A1 (en) 2010-10-28
CL2008003808A1 (en) 2011-03-11
JP2011507816A (en) 2011-03-10
AR071741A1 (en) 2010-07-14
CA2708716A1 (en) 2009-07-02
MX2010006984A (en) 2010-10-25
DOP2010000189A (en) 2010-08-15
BRPI0822098A2 (en) 2015-06-30
TW200940086A (en) 2009-10-01
IL206308A0 (en) 2010-12-30
ZA201004304B (en) 2012-11-28

Similar Documents

Publication Publication Date Title
PE20091528A1 (en) VACCINES AGAINST MALARIA
MX2018010586A (en) STING ACTIVATION NANOVACUNA FOR IMMUNOTHERAPY.
MX363380B (en) FORMULATION OF ANTIBODIES.
BR112016008576A2 (en) STABLE AQUEOUS FORMULATIONS OF ANTIBODIES AND PHARMACEUTICAL UNIT DOSAGE FORM
AR067087A1 (en) VACCINE COMPOSITION AND METHOD TO PREPARE IT
EA201591888A1 (en) REPLICATION-DEFECT VACCINES AND VACCINE VECTORS AGAINST FLAVIVIRUSS
CL2011001993A1 (en) Immunogenic composition comprising at least one inactivated dengue virus antigen and an adjuvant without aluminum; Method of production; and its use to prevent, improve or treat a dengue virus productive disease in a subject.
BR112018004242A2 (en) vaccine compositions having increased stability and immunogenicity
BR112014024612A2 (en) nucleic acid, polypeptide, glycoprotein and chimeric, dengue virus epitope, chimeric flavivirus-like particle (vlp), chimeric flavivirus, and in vitro methods to identify a neutralizing antibody and to identify an immunogenic composition against a dengue virus
WO2015089492A3 (en) Dna antibody constructs and method of using same
AR101455A1 (en) CARRIER MOLECULE
ECSP15007345A (en) METHODS FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS
MX2017007187A (en) Dna antibody constructs and method of using same.
MX2019005137A (en) VACCINE AGAINST PORCINE PARVOVIRUS.
UY36395A (en) VACCINES AGAINST DISEASE OF HANDS, FEET AND MOUTH AND MANUFACTURING METHODS AND ITS USE.
BR112015001313A2 (en) vaccine compositions
PE20140255A1 (en) DISPERSIBLE TABLET IN ORAL FORM
BR112015004515A2 (en) immunogenic composition
AR108829A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS
UY36394A (en) VACCINES AGAINST DISEASE OF HANDS, FEET AND MOUTH AND MANUFACTURING METHODS AND ITS USE.
MX391930B (en) FOOT-AND-MOUTH DISEASE VACCINE.
BRPI0818718B8 (en) process of preparing a vaccine composition comprising antigen and adjuvant in the form of inverse latex of acrylic acid homopolymer
BR112018077397A2 (en) diprovocims: a class of tlr agonists
MX2011006516A (en) HEPATITIS C. VIRUS COMBINATION THERAPY
EA201200538A1 (en) ARABINOGALAKTAN TO IMPROVE ACQUIRED IMMUNE RESPONSE

Legal Events

Date Code Title Description
FD Application declared void or lapsed